ALNY
Income statement / Annual
Last year (2023), Alnylam Pharmaceuticals, Inc.'s total revenue was $1.83 B,
an increase of 76.23% from the previous year.
In 2023, Alnylam Pharmaceuticals, Inc.'s net income was -$440.24 M.
See Alnylam Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.83 B
|
$1.04 B
|
$844.29 M
|
$492.85 M
|
$219.75 M
|
$74.91 M
|
$89.91 M
|
$47.16 M
|
$41.10 M
|
$50.56 M
|
| Cost of Revenue |
$310.41 M |
$168.82 M |
$140.14 M |
$78.05 M |
$25.06 M |
$1.80 M |
$13.37 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$1.52 B |
$868.60 M |
$704.14 M |
$414.80 M |
$194.69 M |
$73.11 M |
$76.55 M |
$47.16 M |
$41.10 M |
$50.56 M |
| Gross Profit Ratio |
0.83 |
0.84 |
0.83 |
0.84 |
0.89 |
0.98 |
0.85 |
1 |
1 |
1 |
| Research and Development
Expenses |
$1.00 B
|
$883.02 M
|
$792.16 M
|
$654.82 M
|
$655.11 M
|
$505.42 M
|
$390.64 M
|
$382.39 M
|
$276.50 M
|
$190.25 M
|
| General & Administrative
Expenses |
$795.65 M
|
$770.66 M
|
$620.64 M
|
$588.42 M
|
$479.01 M
|
$382.36 M
|
$199.37 M
|
$89.35 M
|
$60.61 M
|
$44.53 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$795.65 M
|
$770.66 M
|
$620.64 M
|
$588.42 M
|
$479.01 M
|
$382.36 M
|
$199.37 M
|
$89.35 M
|
$60.61 M
|
$44.53 M
|
| Other Expenses |
-$17.74 M |
-$109.37 M |
-$2.05 M |
$45.53 M |
$20.73 M |
$4.17 M |
-$3.02 M |
$6.17 M |
$76,000.00 |
$1.82 M |
| Operating Expenses |
$1.80 B |
$1.65 B |
$1.41 B |
$1.24 B |
$1.13 B |
$887.78 M |
$590.00 M |
$471.75 M |
$337.11 M |
$234.78 M |
| Cost And Expenses |
$2.11 B |
$1.82 B |
$1.55 B |
$1.32 B |
$1.16 B |
$889.58 M |
$590.00 M |
$471.75 M |
$337.11 M |
$234.78 M |
| Interest Income |
$95.56 M |
$24.81 M |
$1.58 M |
$11.81 M |
$33.45 M |
$29.26 M |
$12.24 M |
$8.31 M |
$5.86 M |
$2.56 M |
| Interest Expense |
$121.22 M |
$155.97 M |
$143.02 M |
$84.50 M |
$0.00 |
$29.26 M |
$12.24 M |
$8.31 M |
$5.86 M |
$2.56 M |
| Depreciation &
Amortization |
$54.05 M
|
$44.47 M
|
$47.57 M
|
$34.77 M
|
$17.18 M
|
$6.44 M
|
$13.37 M
|
$15.13 M
|
$19.05 M
|
$11.93 M
|
| EBITDA |
-$228.12 M
|
-$894.44 M
|
-$709.12 M
|
-$771.10 M
|
-$939.43 M
|
-$835.24 M
|
-$500.09 M
|
-$424.59 M
|
-$296.01 M
|
$36.55 M
|
| EBITDA Ratio |
-0.12 |
-0.86 |
-0.84 |
-1.56 |
-4.27 |
-11.15 |
-5.56 |
-9 |
-7.2 |
0.72 |
| Operating Income Ratio
|
-0.15
|
-0.76
|
-0.84
|
-1.68
|
-4.27
|
-10.88
|
-5.56
|
-9
|
-7.2
|
-8.01
|
| Total Other
Income/Expenses Net |
-$151.34 M
|
-$341.92 M
|
-$143.49 M
|
-$27.16 M
|
$54.18 M
|
$24.74 M
|
-$3.02 M
|
$6.17 M
|
$76,000.00
|
-$218.95 M
|
| Income Before Tax |
-$433.52 M |
-$1.13 B |
-$852.14 M |
-$855.60 M |
-$885.25 M |
-$760.67 M |
-$490.87 M |
-$410.11 M |
-$290.07 M |
-$400.60 M |
| Income Before Tax Ratio
|
-0.24
|
-1.09
|
-1.01
|
-1.74
|
-4.03
|
-10.15
|
-5.46
|
-8.7
|
-7.06
|
-7.92
|
| Income Tax Expense |
$6.73 M |
$4.16 M |
$680,000.00 |
$2.68 M |
$863,000.00 |
$823,000.00 |
-$25.60 M |
-$23.44 M |
-$24.91 M |
-$40.21 M |
| Net Income |
-$440.24 M |
-$1.13 B |
-$852.82 M |
-$858.28 M |
-$886.12 M |
-$761.50 M |
-$490.87 M |
-$410.11 M |
-$290.07 M |
-$360.40 M |
| Net Income Ratio |
-0.24 |
-1.09 |
-1.01 |
-1.74 |
-4.03 |
-10.17 |
-5.46 |
-8.7 |
-7.06 |
-7.13 |
| EPS |
-3.52 |
-9.3 |
-7.2 |
-7.46 |
-8.11 |
-7.57 |
-5.42 |
-4.79 |
-3.45 |
-4.85 |
| EPS Diluted |
-3.52 |
-9.3 |
-7.2 |
-7.46 |
-8.11 |
-7.57 |
-5.42 |
-4.79 |
-3.45 |
-4.85 |
| Weighted Average Shares
Out |
$124.91 M
|
$121.69 M
|
$118.45 M
|
$114.99 M
|
$109.26 M
|
$100.59 M
|
$90.55 M
|
$85.60 M
|
$83.99 M
|
$74.28 M
|
| Weighted Average Shares
Out Diluted |
$124.91 M
|
$121.69 M
|
$118.45 M
|
$114.99 M
|
$109.26 M
|
$100.59 M
|
$90.55 M
|
$85.60 M
|
$83.99 M
|
$74.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
